Stockscreener 앱 받기
9.00
1.10%
-0.10
시간 외 거래:
9.05
0.05
+0.56%
전일 마감가:
$9.10
열려 있는:
$9
하루 거래량:
3.67M
Relative Volume:
0.55
시가총액:
$2.34B
수익:
$6.28B
순이익/손실:
$700.00M
주가수익비율:
3.343
EPS:
2.6922
순현금흐름:
$537.00M
1주 성능:
-4.86%
1개월 성능:
+25.35%
6개월 성능:
-11.85%
1년 성능:
-44.65%
1일 변동 폭
$8.86
$9.215
1주일 범위
$8.86
$9.94
52주 변동 폭
$6.18
$17.23
오가논 & Co Stock (OGN) Company Profile
명칭
Organon Co
전화
551-430-6000
주소
30 HUDSON STREET, JERSEY CITY
OGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
9.00 | 2.37B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
1,039.51 | 951.18B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
224.44 | 533.63B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.93 | 390.19B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
152.22 | 286.13B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.89 | 284.29B | 46.69B | 15.29B | 9.25B | 3.4329 |
오가논 & Co Stock (OGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-10-27 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-09-06 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-11-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-09-21 | 개시 | Barclays | Overweight |
| 2023-03-16 | 개시 | Raymond James | Outperform |
| 2022-10-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 개시 | Piper Sandler | Neutral |
| 2021-09-01 | 개시 | BofA Securities | Buy |
| 2021-07-22 | 개시 | Citigroup | Buy |
| 2021-06-15 | 개시 | JP Morgan | Neutral |
| 2021-06-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 개시 | Evercore ISI | Outperform |
모두보기
오가논 & Co 주식(OGN)의 최신 뉴스
Organon (OGN) Stock Sinks As Market Gains: What You Should Know - sharewise.com
Valuation Update: Is Organon Co subject to activist investor interest2025 Pullback Review & Fast Entry Momentum Alerts - baoquankhu1.vn
543,711 Shares in Organon & Co. $OGN Purchased by Sector Gamma AS - MarketBeat
Organon & Co (OGN) Is Quietly Moving – Is This ‘Boring’ Stock Actually a Game-Changer for Your - AD HOC NEWS
Sun Pharma Bid Puts Organon Valuation And Growth Prospects In Focus - Sahm
(OGN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Acquisition Speculation and Regulatory Approval Drive Organon Shares - AD HOC NEWS
Organon Lures Sun Pharma With Low Valuation & Global Reach—What’s Next? - Smartkarma
Organon gains on report of Sun Pharmaceutical interest - MSN
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report - AOL.com
Sun Pharma again on the prowl in the US market for acquisitions - Fortune India
Sun Pharma Weighs Potential $10 Billion Bid for Organon; Shares See Volatility - Whalesbook
Sun Pharma is said to mull bid for women’s wellness firm Organon - BusinessLine
India’s Biggest Pharma Firm Said to Mull Bid for New York-Listed Organon - Bloomberg.com
Organon (OGN) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Organon acquisition buzz brings Sun Pharma deal strategy back - MSN
Sun Pharma Receives Buy Rating with ₹2,100 Target Price Amid Organon Acquisition Plans - scanx.trade
Massachusetts Financial Services Co. MA Has $101.48 Million Stake in Organon & Co. $OGN - MarketBeat
Barclays Initiates Organon & Co(OGN.US) With Sell Rating, Announces Target Price $7.5 - 富途牛牛
Why Sun Pharma’s hefty bid for Organon has divided investors | Company Business News - Mint
Organon & Co. (NYSE:OGN) Trading Up 8.8%What's Next? - MarketBeat
Why Are Organon (OGN) Shares Soaring Today - Finviz
Organon Stock Surges After FDA Nod for Nexplanon Expansion - StocksToTrade
Organon Secures FDA Approval Extending NEXPLANON Use to Five Years - Yahoo Finance
Sun Pharmaceutical Makes Non-Binding Offer to Acquire Organon for $10B-$14B - Intellectia AI
Aug Breakouts: Is 60 Degrees Pharmaceuticals Inc. Equity Warrant attractive at current valuationMarket Risk Analysis & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Sun Pharmaceutical Evaluates Organon Acquisition to Scale US Business - Chemical Industry Digest
BRIEF—Sun Pharma clarifies $10 billion Organon acquisition report - The Pharma Letter
Sun Pharma looks to rise in US with $10 billion Organon buy - The Economic Times
Sun Pharma places non-binding offer for US-based Organon in its boldest global bet ever - The Economic Times
Organon announces U.S. FDA approved sNDA for Nexplanon - TipRanks
FDA expands use of Organon’s contraception implant up to 5 years - Medical Device Network
Sun Pharma says talk of $10bn Organon bid is 'speculative' - pharmaphorum
Sun Pharma terms $10 billion Organon acquisition reports 'speculative' - Business Standard
Sun Pharma terms $10-billion Organon buy report as 'speculative' - Moneycontrol
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque - BioSpace
Sun Pharma tight-lipped over rumoured $10B deal for Organon - FirstWord Pharma
M&A News: India’s Sun Pharma Eyes $10B Bid for U.S.’ Organon - TipRanks
Sun Pharma clarifies $10 bn Organon acquisition report, calls it 'speculative in nature' - The Economic Times
Sun Pharmaceutical Industries Denies $10 Billion Organon Acquisition Rumors - scanx.trade
India’s Sun Pharma weighs $10 bln bid for US-listed Organon, ET reports By Investing.com - Investing.com South Africa
India’s Sun Pharma weighs $10 bln bid for US-listed Organon, ET reports - Investing.com
Sun Pharma Officially Denies $10 Billion Organon Acquisition Speculation - scanx.trade
Organon (OGN) Receives FDA Approval for Nexplanon Label Expansion to 5 Years - Intellectia AI
Organon wins FDA nod to expand use of Nexplanon birth control implant - Seeking Alpha
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Exte - PharmiWeb.com
Birth control implant Nexplanon now approved to last 5 years in US - Stock Titan
Organon (OGN) Receives FDA Approval to Extend NEXPLANON Use to 5 Years - Intellectia AI
Organon (OGN) Receives FDA Approval for NEXPLANON Extended Use Up to 5 Years - Intellectia AI
Performance Recap: Whats the beta of Organon Co stockJuly 2025 Earnings & Detailed Earnings Play Alerts - baoquankhu1.vn
Global Organon employees on leading Pride Network and building inclusive workplaces - attitude.co.uk
오가논 & Co (OGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.34%
1.70%
자본화:
|
볼륨(24시간):